ImmunityBio (IBRX) Extends Rally on 8th Day on Strong Clinical Trial Results

We recently published 10 Stocks Leaving Wall Street in the Dust; 4 Hit Fresh Records. ImmunityBio Inc. (NASDAQ:IBRX) was one of the top performers on Tuesday.

ImmunityBio extended its winning streak to an 8^th straight day on Tuesday, jumping 8.88 percent to finish at $2.82 apiece as investors cheered positive results from its clinical trial of Anktiva in combination with a checkpoint inhibitor on patients with non-small cell lung cancer (NSCLC).

In an updated report, ImmunityBio Inc. (NASDAQ:IBRX) said that Anktiva plus CPI showed statistically significant immune restoration and a consistent association between lymphocyte recovery and improved survival across 151 patients enrolled in two studies.

Checkpoint inhibitors such as pembrolizumab (Keytruda) and nivolumab (Opdivo) have transformed the treatment landscape for lung cancer. However, ImmunityBio Inc. (NASDAQ:IBRX) said that clinical benefit is often transient, and effective treatment options remain limited once patients progress following standard-of-care chemo-radiation and checkpoint inhibition.

ImmunityBio Inc. (NASDAQ:IBRX) said that detailed results from both studies are being prepared for peer-review publication and future scientific presentations and serve as foundational safety and efficacy data demonstrating meaningful clinical benefit in patients with NSCLC who have failed all standards of care including checkpoint inhibitors.

While we acknowledge the potential of IBRX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.